Agenus advances Phase 3 ROBBIN trial of BOT+BAL in MSS colon cancer
Agenus reported Q2 2026 results and announced an accelerated Phase 3 trial for neoadjuvant colon cancer. The trial is fully funded via a July 2026 private placement and addresses a multi-billion dollar annual market opportunity.
View filing at SEC.gov →